Healthcare

Revenue rose 12.7% to A$10.867 billion and underlying EBITDA increased 10.6% to A$1.933 billion. Statutory net profit after tax reached A$608 million, whileUnderlying Profitwas A$621 million. Pathology remained the largest contributor, with radiology adding diversification. Acquisitions in Germany and the United States helped expand …

For the six months to June 2026, service revenue edged up 0.5% to A$2.071 billion, while EBITDA increased 4.5% to A$821 million. TheMarginexpanded to 33.9%. TPG added 64,000 net mobile subscribers, taking the base to 5.806 million, and mobile average revenue per user reached …

One of the most notable 2026 renewals was announced on 13 April, when Pro Medicus confirmed a five-year A$37M renewal with Northwestern Medicine for Visage 7 Viewer. The renewal was negotiated with higher minimum commitments and an increased fee per transaction. Management said the …

Lumos Diagnostics Holdings (ASX:LDX) closed at AUD 0.11 on 6 October 2026 after gaining 10.00% for the session. The double-digit advance gives the company renewed visibility at a time when its operating agenda is focused on point-of-care diagnostic products, including the FebriDx rapid test. …

ReNerve Limited (ASX:RNV) is an Australian medical device company focused on products for peripheral nerve injury repair. In its 2026 AGM presentation, the company said recruitment for the Align clinical study of its NervAlign Nerve Cuff is nearing completion, with final study data expected …

The company said the commercial release was dated 5 October 2026. CAP24 is a surgical paddle lead designed for use with the Evoke System. Saluda described the device as low-profile and anatomically contoured, with the design intended to support stablePlacementand broad stimulation coverage. The …

Neurizon Therapeutics Limited (ASX:NUZ) is an Australian clinical-stage biotechnology company focused on developing investigational treatments for neurodegenerative diseases, with NUZ-001 currently being evaluated for amyotrophic lateral sclerosis (ALS). On 6 October 2026, the company reported written feedback from the US Food and Drug Administration …